The Place of Chemotherapy in The Evolving Treatment Landscape for Patients With HR-positive/HER2-negative MBC.

Antineoplastic Agents / therapeutic use Antineoplastic Combined Chemotherapy Protocols / therapeutic use Breast Neoplasms / pathology Female Humans Neoplasm Metastasis Receptor, ErbB-2 / metabolism
Chemotherapy Cytotoxic HR positive Metastatic breast cancer

Journal

Clinical breast cancer
ISSN: 1938-0666
Titre abrégé: Clin Breast Cancer
Pays: United States
ID NLM: 100898731

Informations de publication

Date de publication:
04 2022
Historique:
received: 12 04 2021
revised: 23 07 2021
accepted: 19 10 2021
pubmed: 1 12 2021
medline: 3 5 2022
entrez: 30 11 2021
Statut: ppublish

Résumé

Endocrine therapy (ET) for the treatment of patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR-positive/HER2-negative) metastatic breast cancer (MBC) has changed markedly over recent years with the emergence of new ETs and the use of molecularly targeted agents. Cytotoxic chemotherapy continues, however, to have an important role in these patients and it is important to maximize its efficacy while minimizing toxicity to optimize outcomes. This review examines current HR-positive/HER2-negative MBC clinical guidelines and addresses key questions around the use of chemotherapy in the face of emerging therapeutic options. Specifically, the indications for chemotherapy in patients with HR-positive/HER2-negative MBC and the choice of optimal chemotherapy are discussed.

Identifiants

DOI: 10.1016/j.clbc.2021.10.007 PMID: 34844889
pubmed: 34844889
pii: S1526-8209(21)00301-3
doi: 10.1016/j.clbc.2021.10.007
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Receptor, ErbB-2 EC 2.7.10.1

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

223-234

Informations de copyright

Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Chris Twelves (C)

Clinical Cancer Pharmacology and Oncology, Leeds Institute of Medical Research, University of Leeds and Leeds Teaching Hospitals Trust Leeds. Electronic address: c.j.twelves@leeds.ac.uk.

Rupert Bartsch (R)

Department of Medicine 1, Division of Oncology, Medical University of Vienna, Austria.

Noa Efrat Ben-Baruch (NE)

Department of Oncology, Kaplan Medical Center, Rehovot, Israel.

Simona Borstnar (S)

Division of Medical Oncology, Institute of Oncology, Ljubljana, Slovenia.

Luc Dirix (L)

Medical Oncology, Sint-Augustinus Hospital, Antwerp, Belgium.

Petra Tesarova (P)

First Faculty of Medicine and General Teaching Hospital, Charles University, Prague, Czech Republic.

Constanta Timcheva (C)

Medical Oncology MHAT "Nadezhda", Sofia, Bulgaria.

Lyudmila Zhukova (L)

Loginov Moscow Clinical Scientific Center, Moscow, Russia.

Xavier Pivot (X)

ICANS - Strasbourg Europe Cancerology Institute, Strasbourg, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antinéoplasiques › The Place of Chemotherapy in The Evolving...
questionsmedicales.fr › Thérapeutique › Traitement médicamenteux › Association de médicaments › Protocoles de polychimiothérapie antinéoplasique › The Place of Chemotherapy in The Evolving...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Maladies du sein › Tumeurs du sein › The Place of Chemotherapy in The Evolving...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › The Place of Chemotherapy in The Evolving...
questionsmedicales.fr › États, signes et symptômes pathologiques › Processus pathologiques › Processus néoplasiques › Métastase tumorale › The Place of Chemotherapy in The Evolving...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Marqueurs biologiques tumoraux › Récepteur ErbB-2 › The Place of Chemotherapy in The Evolving...